SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Psykiatri) srt2:(2010-2019)"

Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Psykiatri) > (2010-2019)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Johansson, Per, et al. (författare)
  • Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment.
  • 2017
  • Ingår i: PloS one. - 1932-6203. ; 12:5
  • Tidskriftsartikel (refereegranskat)abstract
    • Background The role of inflammation in Alzheimer’s disease (AD) and other cognitive disorders is unclear. In a well-defined mono-center population, we measured cytokines and chemokines in paired serum and cerebrospinal fluid (CSF) samples. Methods Consecutive patients with AD (n = 30), stable mild cognitive impairment (SMCI, n = 11), other dementias (n = 11), and healthy controls (n = 18) were included. None of the subjects was treated with glucocorticoids, cholinesterase inhibitors, or non-steroidal anti-inflammatory drugs. Serum and CSF concentrations of interleukin-6 (IL-6), IL-8, IL-12/23 p40, IL-15, IL-16, vascular endothelial growth factor-A (VEGF-A), and three chemokines were measured using a multiplex panel. Results After correction for multiple comparisons, only CSF IL-12/23 p40 concentration differed significantly between the total patient group (n = 52) and controls (n = 18; p = 0.002). Further analyses showed that CSF IL-12/23 p40 concentration was decreased in all patient subgroups (AD, other dementias, and SMCI) compared to healthy controls (p < 0.01, p < 0.05, and p < 0.05, respectively). In the total study population (n = 70), CSF IL-12/23 p40 concentrations correlated positively with CSF concentrations of β-amyloid1-42 (Aβ1–42) and phosphorylated tau protein (P-tau) whereas in AD patients (n = 30), CSF IL-12/23 p40 only correlated positively with CSF P-Tau (r = 0.46, p = 0.01). Conclusions Most cytokines and chemokines were similar in patients and controls, but CSF IL-12/23 subunit p40 concentration was decreased in patients with cognitive impairment, and correlated with markers of AD disease status. Further studies are needed to evaluate the role of CSF IL-12/23 p40 in other dementias and SMCI.
2.
  • Paterson, R. W., et al. (författare)
  • A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.
  • 2016
  • Ingår i: Translational psychiatry. - 2158-3188. ; 6:11
  • Tidskriftsartikel (refereegranskat)abstract
    • Alzheimer's disease (AD) is the most common cause of dementia. Biomarkers are required to identify individuals in the preclinical phase, explain phenotypic diversity, measure progression and estimate prognosis. The development of assays to validate candidate biomarkers is costly and time-consuming. Targeted proteomics is an attractive means of quantifying novel proteins in cerebrospinal and other fluids, and has potential to help overcome this bottleneck in biomarker development. We used a previously validated multiplexed 10-min, targeted proteomic assay to assess 54 candidate cerebrospinal fluid (CSF) biomarkers in two independent cohorts comprising individuals with neurodegenerative dementias and healthy controls. Individuals were classified as 'AD' or 'non-AD' on the basis of their CSF T-tau and amyloid Aβ1-42 profile measured using enzyme-linked immunosorbent assay; biomarkers of interest were compared using univariate and multivariate analyses. In all, 35/31 individuals in Cohort 1 and 46/36 in Cohort 2 fulfilled criteria for AD/non-AD profile CSF, respectively. After adjustment for multiple comparisons, five proteins were elevated significantly in AD CSF compared with non-AD CSF in both cohorts: malate dehydrogenase; total APOE; chitinase-3-like protein 1 (YKL-40); osteopontin and cystatin C. In an independent multivariate orthogonal projection to latent structures discriminant analysis (OPLS-DA), these proteins were also identified as major contributors to the separation between AD and non-AD in both cohorts. Independent of CSF Aβ1-42 and tau, a combination of these biomarkers differentiated AD and non-AD with an area under curve (AUC)=0.88. This targeted proteomic multiple reaction monitoring (MRM)-based assay can simultaneously and rapidly measure multiple candidate CSF biomarkers. Applying this technique to AD we demonstrate differences in proteins involved in glucose metabolism and neuroinflammation that collectively have potential clinical diagnostic utility.
3.
  • Gustafson, Lars, et al. (författare)
  • A factor analytic approach to symptom patterns in dementia.
  • 2010
  • Ingår i: International Journal of Alzheimer's Disease. - Hindawi Publishing Corporation. - 2090-0252.
  • Tidskriftsartikel (refereegranskat)abstract
    • Previous publications have shown a high diagnostic sensitivity and specificity of three short clinical rating scales for Alzheimer's disease (AD), frontotemporal dementia (FTD), and vascular dementia (VaD) validated against neuropathological (NP) diagnoses. In this study, the aim was to perform an exploratory factor analysis of the items in these clinical rating scales. The study included 190 patients with postmortem diagnoses of AD (n = 74), VaD (n = 33), mixed AD/VaD (n = 31), or FTD (n = 52). The factor analysis produced three strong factors. Factor 1 contained items describing cerebrovascular disease, similar to the Hachinski Ischemic Score. Factor 2 enclosed major clinical characteristics of FTD, and factor 3 showed a striking similarity to the AD scale. A fourth symptom cluster was described by perception and expression of emotions. The factor analyses strongly support the construct validity of the diagnostic rating scales.
4.
  • Palmqvist, Sebastian, et al. (författare)
  • Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
  • 2015
  • Ingår i: Neurology. - American Academy of Neurology. - 1526-632X. ; 85:14, s. 1240-1249
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective:To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for diagnosing early-stage Alzheimer disease (AD).Methods:From the prospective, longitudinal BioFINDER study, we included 122 healthy elderly and 34 patients with mild cognitive impairment who developed AD dementia within 3 years (MCI-AD). -Amyloid (A) deposition in 9 brain regions was examined with [F-18]-flutemetamol PET. CSF was analyzed with INNOTEST and EUROIMMUN ELISAs. The results were replicated in 146 controls and 64 patients with MCI-AD from the Alzheimer's Disease Neuroimaging Initiative study.Results:The best CSF measures for identifying MCI-AD were A42/total tau (t-tau) and A42/hyperphosphorylated tau (p-tau) (area under the curve [AUC] 0.93-0.94). The best PET measures performed similarly (AUC 0.92-0.93; anterior cingulate, posterior cingulate/precuneus, and global neocortical uptake). CSF A42/t-tau and A42/p-tau performed better than CSF A42 and A42/40 (AUC difference 0.03-0.12, p < 0.05). Using nonoptimized cutoffs, CSF A42/t-tau had the highest accuracy of all CSF/PET biomarkers (sensitivity 97%, specificity 83%). The combination of CSF and PET was not better than using either biomarker separately.Conclusions:Amyloid PET and CSF biomarkers can identify early AD with high accuracy. There were no differences between the best CSF and PET measures and no improvement when combining them. Regional PET measures were not better than assessing the global A deposition. The results were replicated in an independent cohort using another CSF assay and PET tracer. The choice between CSF and amyloid PET biomarkers for identifying early AD can be based on availability, costs, and doctor/patient preferences since both have equally high diagnostic accuracy.Classification of evidence:This study provides Class III evidence that amyloid PET and CSF biomarkers identify early-stage AD equally accurately.
5.
  • Schöll, Michael, 1980-, et al. (författare)
  • Biomarkers for tau pathology.
  • 2019
  • Ingår i: Molecular and cellular neurosciences. - 1095-9327. ; 97, s. 18-33
  • Forskningsöversikt (refereegranskat)abstract
    • The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-associated tau protein characterizes 80% of all dementia disorders, the most common neurodegenerative disorders. These so-called tauopathies are hitherto not curable and their diagnosis, especially at early disease stages, has traditionally proven difficult. A keystone in the diagnosis of tauopathies was the development of methods to assess levels of tau protein in vivo in cerebrospinal fluid, which has significantly improved our knowledge about these conditions. Tau proteins have also been measured in blood, but the importance of tau-related changes in blood is still unclear. The recent addition of positron emission tomography ligands to visualize, map and quantify tau pathology has further contributed with information about the temporal and spatial characteristics of tau accumulation in the living brain. Together, the measurement of tau with fluid biomarkers and positron emission tomography constitutes the basis for a highly active field of research. This review describes the current state of biomarkers for tau biomarkers derived from neuroimaging and from the analysis of bodily fluids and their roles in the detection, diagnosis and prognosis of tau-associated neurodegenerative disorders, as well as their associations with neuropathological findings, and aims to provide a perspective on how these biomarkers might be employed prospectively in research and clinical settings.
  •  
6.
  • Burman, Joachim, et al. (författare)
  • Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: : the Swedish experience
  • 2014
  • Ingår i: Journal of Neurology, Neurosurgery and Psychiatry. - BMJ Publishing Group. - 0022-3050. ; 85:10, s. 1116-1121
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. In this observational study, we describe the characteristics and outcome of the Swedish patients treated with HSCT for MS. Methods Neurologists from the major hospitals in Sweden filled out a follow-up form with prospectively collected data. Fifty-two patients were identified in total; 48 were included in the study and evaluated for safety and side effects; 41 patients had at least 1 year of follow-up and were further analysed for clinical and radiological outcome. In this cohort, 34 patients (83%) had relapsing-remitting MS, and mean follow-up time was 47 months. Results At 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status scale (EDSS) score progression-free survival 77%; and disease-free survival (no relapses, no new MRI lesions and no EDSS progression) 68%. Presence of gadolinium-enhancing lesions prior to HSCT was associated with a favourable outcome (disease-free survival 79% vs 46%, p=0.028). There was no mortality. The most common long-term side effects were herpes zoster reactivation (15%) and thyroid disease (8.4%). Conclusions HSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres.
  •  
7.
  • Nero, Daniella, et al. (författare)
  • Personality Traits in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries
  • 2019
  • Ingår i: American Journal of Medicine. - 0002-9343. ; 132:3, s. 374-381
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: The purpose of this study was to describe type A behavior pattern and trait anger in patients with myocardial infarction with nonobstructive coronary arteries (MINOCA) and compare them with patients with coronary heart disease and healthy controls. Type A behavior pattern and anger have been linked to coronary heart disease in previous studies. This is the first study to assess type A behavior pattern and trait anger in MINOCA patients. Methods: One hundred MINOCA patients, consecutively recruited during 2007-2011 at 5 coronary care units in Stockholm, were matched for sex and age to 100 coronary heart disease patients and 100 healthy controls. All participants completed the Bortner Rating Scale to quantify type A behavior pattern and the Spielberger Trait Anger Scale to quantify anger 3 months after the acute event. Results: MINOCA patients’ Bortner Rating Scale score was 70.9 ± 10.8 (mean ± SD) and Spielberger Trait Anger Scale score was 14 (12-17) (median; interquartile range). Coronary heart disease patients’ Bortner Rating Scale score was 70.5 ± 10.2 and Spielberger Trait Anger Scale score was 14 (12-17). Healthy controls’ Bortner Rating Scale score was 71.9 ± 9.1 and Spielberger Trait Anger Scale score was 13 (11-16). Conclusion: We found no significant differences in Bortner Rating Scale score and Spielberger Trait Anger Scale score among MINOCA, coronary heart disease patients, and healthy controls, regardless of whether total scores, subscales, or cutoffs were used to classify type A behavior pattern and trait anger. However, we cannot exclude the existence of an occasional episode of anger or mental stress in relation to the coronary event. This is the first study to assess type A behavior pattern and trait anger in patients with MINOCA, and future studies need to confirm the current findings before any firm conclusions can be made. 
  •  
8.
  • Shahim, Pashtun, et al. (författare)
  • Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer’s Disease and Other Neurodegenerative Disorders
  • 2017
  • Ingår i: NeuroMolecular Medicine. - 1535-1084 .- 1559-1174. ; 19:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Stanniocalcin-1 (STC-1) is a nerve cell-enriched protein involved in intracellular calcium homeostasis regulation. Changes in calcium regulation are hypothesized to play a role in the pathophysiology of Alzheimer's disease (AD). The expression of STC-1 increases in response to ischemic stroke, but whether it is altered in neurodegenerative disorder, particularly Alzheimer's disease (AD), has not been investigated before. We measured STC-1 in cerebrospinal fluid (CSF) samples from a total of 163 individuals including AD, prodromal AD (pAD), mixed AD, stable mild cognitive impairment (sMCI), and diagnoses of other dementia than AD, as well as cognitively normal controls (CNC) enrolled at academic centers in France and Sweden. STC-1 concentration was reliably measureable in all CSF samples and was significantly increased in the initial exploratory cohort of neurochemically enriched AD patients versus AD biomarker-negative controls. In the second cohort, STC-1 was increased in AD versus pAD, and other dementia disorders, but the difference was not statistically significant. In the third cohort, there was no significant difference in STC-1 concentration between AD and CNC; however, STC-1 concentration was significantly decreased in patients with other dementia disorders compared with AD and CNC. Taken together, CSF STC-1 showed an increasing trend in AD, but the findings were not consistent across the three study cohorts. In contrast, CSF STC-1 concentrations were reduced in patients with dementia diagnoses other than AD, as compared with both AD patients and CNC. The findings from these studies suggest CSF STC-1 as a potential biomarker in differential diagnosis of dementias.
  •  
9.
10.
  • Brun, Arne, et al. (författare)
  • The Birth and Early Evolution of the Frontotemporal Dementia (FTD) Concept.
  • 2011
  • Ingår i: Journal of Molecular Neuroscience : MN. - Humana Press. - 1559-1166. ; 45, s. 324-329
  • Tidskriftsartikel (refereegranskat)abstract
    • An historical overview of the development of the concept of frontotemporal dementia is presented, regarding the last 30 years, using as a backbone the conferences held on this theme, with a start in 1986 in Lund, Sweden. Since then, a dramatic increase in research activities and publications has rapidly expanded our knowledge in this field, a step necessary for the ultimate goal to find an effective treatment of this devastating disorder.
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (1011)
Typ av publikation
tidskriftsartikel (3098)
konferensbidrag (134)
doktorsavhandling (114)
forskningsöversikt (103)
bokkapitel (100)
rapport (41)
visa fler...
bok (24)
annan publikation (15)
samlingsverk (redaktörskap) (9)
recension (5)
patent (1)
visa färre...
Typ av innehåll
refereegranskat (3052)
övrigt vetenskapligt (569)
populärvet., debatt m.m. (22)
Författare/redaktör
Gillberg, Christophe ... (172)
Larsson, Henrik, 197 ... (168)
Lichtenstein, Paul, (165)
Landén, Mikael, 1966 ... (117)
Blennow, Kaj, 1958-, (112)
Zetterberg, Henrik, ... (108)
visa fler...
Landen, M, (105)
Fernell, Elisabeth, (96)
Andersson, Gerhard, (69)
Råstam, Maria, (66)
Anckarsäter, Henrik, (64)
Jokinen, Jussi, (60)
Lundström, Sebastian ... (60)
Gillberg, Christophe ... (59)
Sundquist, Kristina, (56)
Sundquist, Jan, (53)
Waern, Margda, 1955- ... (49)
Anckarsäter, Henrik, ... (48)
Langstrom, N, (47)
Skoog, Ingmar, 1954- ... (45)
Lichtenstein, P, (44)
Lundstrom, S (42)
Kuja-Halkola, Ralf, (42)
D'Onofrio, Brian M. (42)
Garcia, Danilo, 1973 ... (41)
Almqvist, Catarina (41)
Ekselius, Lisa, (40)
Blennow, Kaj (40)
Svedin, Carl Göran (40)
Anckarsater, H (40)
Långström, Niklas (39)
Carlbring, Per, (38)
Bejerot, Susanne, 19 ... (38)
Landén, Mikael (37)
Adolfsson, Rolf, (36)
Minthon, Lennart, (35)
Wallin, Anders, 1950 ... (34)
Billstedt, Eva, 1961 ... (34)
Zetterberg, Henrik, (33)
Hansson, Oskar, (32)
Leboyer, Marion (31)
Ruck, Christian, (31)
Bölte, Sven (29)
Gillberg, I Carina, ... (29)
Lindqvist, Daniel, (29)
Mataix-Cols, David, (29)
Hansson, Lars, (28)
Westrin, Åsa, (28)
Furmark, Tomas, (27)
Serlachius, Eva (27)
visa färre...
Lärosäte
Göteborgs universitet (1238)
Karolinska Institutet (1043)
Lunds universitet (743)
Uppsala universitet (652)
Örebro universitet (463)
Umeå universitet (422)
visa fler...
Stockholms universitet (357)
Linköpings universitet (294)
Linnéuniversitetet (81)
Högskolan i Jönköping (79)
Karlstads universitet (50)
Mittuniversitetet (42)
Malmö universitet (39)
Södertörns högskola (32)
Högskolan Väst (30)
Högskolan i Halmstad (24)
Ersta Sköndal Bräcke högskola (23)
Chalmers tekniska högskola (21)
Högskolan Kristianstad (19)
Sveriges Lantbruksuniversitet (19)
Gymnastik- och idrottshögskolan (19)
Högskolan Dalarna (19)
Röda Korsets Högskola (15)
Högskolan i Gävle (14)
Mälardalens högskola (11)
Kungliga Tekniska Högskolan (10)
Högskolan i Skövde (10)
Blekinge Tekniska Högskola (7)
Högskolan i Borås (6)
Sophiahemmet Högskola (5)
Luleå tekniska universitet (4)
VTI - Statens väg- och transportforskningsinstitut (1)
visa färre...
Språk
Engelska (3410)
Svenska (229)
Norska (2)
Danska (1)
Spanska (1)
Finska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (3644)
Samhällsvetenskap (734)
Humaniora (75)
Naturvetenskap (45)
Teknik (15)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy